drugset / Trial / NCT05594602

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602

Phase 1 Completed 36 enrolled Enanta Pharmaceuticals, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

A Drug-Drug Interaction study to assess the effects of itraconazole, carbamazepine and quinidine on the Pharmacokinetics and Safety of EDP-235.

Timeline

Start
2022-10-06
Primary completion
2022-12-14
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule
Subject EDP-235 Unknown
Subject Itraconazole Small molecule
Subject Quinidine Small molecule

Indications